Financings in Brief: Urologix
This article was originally published in The Gray Sheet
Urologix: Files with SEC for a proposed secondary offering of 1.5 mil. shares of common stock. The Minneapolis maker of minimally invasive devices for treatment of urological diseases received FDA approval Aug. 22 for its Targis microwave therapy device for treating benign prostatic hyperplasia ("The Gray Sheet" Sept. 1, p. 4), and plans to use proceeds from the offering to fund sales and marketing efforts, "to expand manufacturing capacity, and for working capital and other general corporate purposes," the firm says. Underwriters BT Alex. Brown, Dain Bosworth and PaineWebber hold an over-allotment option for 225,000 additional shares...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.